Short Interest in Jaguar Animal Health, Inc. (NASDAQ:JAGX) Expands By 106.8%

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 242,001 shares, an increase of 106.8% from the August 15th total of 117,037 shares. Based on an average trading volume of 151,797 shares, the short-interest ratio is currently 1.6 days. Currently, 4.7% of the shares of the company are sold short.

Analyst Ratings Changes

Several equities analysts recently weighed in on JAGX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Friday, July 17th. Wall Street Zen upgraded Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Jaguar Animal Health presently has a consensus rating of “Sell”.

Jaguar Animal Health Price Performance

JAGX stock traded up $0.01 during mid-day trading on Monday, reaching $0.32. The company’s stock had a trading volume of 434,972 shares, compared to its average volume of 138,995. The company has a current ratio of 0.69, a quick ratio of 0.40 and a debt-to-equity ratio of 0.35. The company’s 50 day moving average is $1.12 and its two-hundred day moving average is $6.81. Jaguar Animal Health has a fifty-two week low of $0.29 and a fifty-two week high of $85.40. The stock has a market cap of $1.65 million, a PE ratio of -0.00 and a beta of -0.07.

Jaguar Animal Health (NASDAQ:JAGX) last posted its quarterly earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($52.15) by $36.45. The company had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $4.24 million.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.